-
Je něco špatně v tomto záznamu ?
Harnessing the Natural Pool of Polyketide and Non-ribosomal Peptide Family: A Route Map towards Novel Drug Development
A. Girija, M. Vijayanathan, S. Sreekumar, J. Basheer, TG. Menon, RE. Krishnankutty, EV. Soniya
Jazyk angličtina Země Spojené arabské emiráty
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
- MeSH
- COVID-19 * MeSH
- farmakoterapie COVID-19 MeSH
- lidé MeSH
- peptidy farmakologie terapeutické užití MeSH
- polyketidy * chemie metabolismus farmakologie MeSH
- SARS-CoV-2 MeSH
- vyvíjení léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
The emergence of communicable and non-communicable diseases has posed a health challenge for millions of people worldwide and is a major threat to the economic and social development in the coming century. The occurrence of the recent pandemic, SARS-CoV-2, caused by lethal severe acute respiratory syndrome coronavirus 2, is one such example. Rapid research and development of drugs for the treatment and management of these diseases have become an incredibly challenging task for the pharmaceutical industry. Although, substantial attention has been paid to the discovery of therapeutic compounds from natural sources having significant medicinal potential, their synthesis has made a slow progress. Hence, the discovery of new targets by the application of the latest biotechnological and synthetic biology approaches is very much the need of the hour. Polyketides (PKs) and non-ribosomal peptides (NRPs) found in bacteria, fungi and plants are a diverse family of natural products synthesized by two classes of enzymes: polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS). These enzymes possess immense biomedical potential due to their simple architecture, catalytic capacity, as well as diversity. With the advent of the latest in-silico and in-vitro strategies, these enzymes and their related metabolic pathways, if targeted, can contribute highly towards the biosynthesis of an array of potentially natural drug leads that have antagonist effects on biopolymers associated with various human diseases. In the face of the rising threat from multidrug-resistant pathogens, this will further open new avenues for the discovery of novel and improved drugs by combining natural and synthetic approaches. This review discusses the relevance of polyketides and non-ribosomal peptides and the improvement strategies for the development of their derivatives and scaffolds, and how they will be beneficial for future bioprospecting and drug discovery.
Institute of Biological Environmental Rural Sciences Aberystwyth University United Kingdom
Research Centre University of Kerala India
School of Biosciences Mahatma Gandhi University PD Hills Kottayam Kerala India
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019513
- 003
- CZ-PrNML
- 005
- 20220804135726.0
- 007
- ta
- 008
- 220720s2022 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1874467214666210319145816 $2 doi
- 035 __
- $a (PubMed)33745440
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Girija, Aiswarya $u Department of Transdisciplinary Biology, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala, India $u Institute of Biological Environmental Rural Sciences (IBERS), Aberystwyth University, United Kingdom
- 245 10
- $a Harnessing the Natural Pool of Polyketide and Non-ribosomal Peptide Family: A Route Map towards Novel Drug Development / $c A. Girija, M. Vijayanathan, S. Sreekumar, J. Basheer, TG. Menon, RE. Krishnankutty, EV. Soniya
- 520 9_
- $a The emergence of communicable and non-communicable diseases has posed a health challenge for millions of people worldwide and is a major threat to the economic and social development in the coming century. The occurrence of the recent pandemic, SARS-CoV-2, caused by lethal severe acute respiratory syndrome coronavirus 2, is one such example. Rapid research and development of drugs for the treatment and management of these diseases have become an incredibly challenging task for the pharmaceutical industry. Although, substantial attention has been paid to the discovery of therapeutic compounds from natural sources having significant medicinal potential, their synthesis has made a slow progress. Hence, the discovery of new targets by the application of the latest biotechnological and synthetic biology approaches is very much the need of the hour. Polyketides (PKs) and non-ribosomal peptides (NRPs) found in bacteria, fungi and plants are a diverse family of natural products synthesized by two classes of enzymes: polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS). These enzymes possess immense biomedical potential due to their simple architecture, catalytic capacity, as well as diversity. With the advent of the latest in-silico and in-vitro strategies, these enzymes and their related metabolic pathways, if targeted, can contribute highly towards the biosynthesis of an array of potentially natural drug leads that have antagonist effects on biopolymers associated with various human diseases. In the face of the rising threat from multidrug-resistant pathogens, this will further open new avenues for the discovery of novel and improved drugs by combining natural and synthetic approaches. This review discusses the relevance of polyketides and non-ribosomal peptides and the improvement strategies for the development of their derivatives and scaffolds, and how they will be beneficial for future bioprospecting and drug discovery.
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a vyvíjení léků $7 D000076722
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a peptidy $x farmakologie $x terapeutické užití $7 D010455
- 650 12
- $a polyketidy $x chemie $x metabolismus $x farmakologie $7 D061065
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vijayanathan, Mallika $u Department of Transdisciplinary Biology, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala, India $u Biology Centre - Institute of Plant Molecular Biology, Czech Academy of Sciences, České Budějovice, 370 05, Czech Republic
- 700 1_
- $a Sreekumar, Sweda $u Department of Transdisciplinary Biology, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala, India $u Research Centre, University of Kerala, India
- 700 1_
- $a Basheer, Jasim $u School of Biosciences, Mahatma Gandhi University, PD Hills, Kottayam, Kerala, India $u Department of Cell Biology, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Menon, Tara G $u Department of Transdisciplinary Biology, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala, India
- 700 1_
- $a Krishnankutty, Radhakrishnan E $u School of Biosciences, Mahatma Gandhi University, PD Hills, Kottayam, Kerala, India
- 700 1_
- $a Soniya, Eppurathu V $u Department of Transdisciplinary Biology, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala, India
- 773 0_
- $w MED00180210 $t Current molecular pharmacology $x 1874-4702 $g Roč. 15, č. 2 (2022), s. 265-291
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33745440 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135719 $b ABA008
- 999 __
- $a ok $b bmc $g 1822917 $s 1170756
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 15 $c 2 $d 265-291 $e - $i 1874-4702 $m Current molecular pharmacology $n Curr Mol Pharmacol $x MED00180210
- LZP __
- $a Pubmed-20220720